Understand acute and chronic leukemia, warning signs, blood and bone marrow testing, and how subtype-specific treatment works.
Leukemia is a group of cancers that begin in blood-forming tissue, usually the bone marrow. Abnormal blood cells multiply or survive when they should not, crowding out healthy red cells, white cells, and platelets. Leukemia is not one disease: acute and chronic forms behave differently, and treatment depends on the exact cell type, genetic features, age, health, and patient goals.
AT A GLANCE
- There are four major groups. They are:
- Acute lymphoblastic leukemia,
- Acute myeloid leukemia,
- Chronic lymphocytic leukemia, and
- Chronic myeloid leukemia.
- While acute leukemias usually worsen quickly and require urgent specialist care, chronic leukemias may be found on routine blood tests and can progress slowly.
- Fatigue, infections, fever, bruising, bleeding, bone pain, swollen lymph nodes, or weight loss can occur. But those symptoms are not specific to leukemia.
- Diagnosis uses a complete blood count, blood smear, and often bone marrow, flow-cytometry, chromosome, and molecular testing.
- There is no routine screening test for leukemia in people without symptoms.
- Treatment can include chemotherapy, targeted medicines, immunotherapy, stem-cell transplant, supportive care, or observation for selected slow-growing disease.
- Fever during treatment or severe bleeding is an emergency.
WHEN TO GET URGENT HELP
Call the oncology team immediately for a fever at or above the threshold they provided, shaking chills, new shortness of breath, uncontrolled vomiting, severe diarrhea, inability to drink, or signs of infection. During chemotherapy or when neutrophils are low, fever can be the only sign of a life-threatening infection. Do not wait for other symptoms or take fever-reducing medicine before calling unless the treatment team has instructed you.
Call 911 for uncontrolled bleeding, coughing or vomiting blood, black stool with weakness, fainting, severe breathlessness, chest pain, confusion, a seizure, one-sided weakness, or a sudden severe headache. Very high leukemia-cell counts can impair blood flow to the brain or lungs. Treatment can also trigger tumor lysis syndrome, causing dangerous electrolyte and kidney problems; symptoms may include weakness, vomiting, cramps, reduced urine, confusion, or abnormal heartbeat.
WHAT LEUKEMIA DOES
Bone marrow makes red blood cells that carry oxygen, white cells that fight infection, and platelets that stop bleeding. A leukemia cell acquires changes that disrupt normal growth or maturation. As abnormal cells accumulate, healthy production falls. This can cause anemia, infection risk, and bleeding.
“Acute” means abnormal immature cells grow rapidly. “Chronic” generally means more mature-looking cells accumulate and disease may progress more slowly. “Lymphoid” refers to lymphocyte-lineage cells; “myeloid” refers to another blood-forming lineage. These categories shape treatment far more than the general word leukemia.
MAIN TYPES
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer but also occurs in adults. It develops from lymphoid precursors and requires prompt therapy. B-cell and T-cell ALL have different features; some cases carry the Philadelphia chromosome or other targetable changes.
Acute myeloid leukemia (AML) is most common in older adults but can occur at any age. It contains many biologically distinct subtypes. Acute promyelocytic leukemia is a specific AML emergency because severe bleeding can occur, yet it is highly treatable with prompt specialized therapy.
Chronic lymphocytic leukemia (CLL) affects mature B lymphocytes and is usually diagnosed in older adults. Some people remain well for years without treatment. Small lymphocytic lymphoma is closely related and classified mainly by where abnormal cells are found.
Chronic myeloid leukemia (CML) usually has the BCR::ABL1 fusion, created by the Philadelphia chromosome. Targeted tyrosine-kinase inhibitors transformed CML outcomes. Monitoring the fusion level helps assess response.
Other leukemias include hairy-cell leukemia, chronic myelomonocytic leukemia, T-cell large granular lymphocytic leukemia, and rare childhood forms. Each needs specialist classification.
SYMPTOMS
Possible features include:
– Persistent fatigue, weakness, or pale skin from anemia
– Fever, night sweats, or repeated infections
– Easy bruising, tiny red-purple spots called petechiae, nosebleeds, or gum bleeding
– Bone or joint pain
– Swollen lymph nodes
– Fullness or discomfort under the ribs from an enlarged spleen or liver
– Unintentional weight loss or reduced appetite
– Shortness of breath
– Headache or neurologic symptoms in uncommon cases
Chronic leukemia may cause no symptoms and be discovered after an abnormal blood count. These signs also occur with infections, nutritional deficiencies, autoimmune conditions, medicines, and other cancers. Symptoms cannot establish the diagnosis.
CAUSES AND RISK FACTORS
Most people did not cause their leukemia, and no single cause is found. Risk varies by type. Factors can include older age, prior chemotherapy or radiation, high-dose radiation exposure, benzene, smoking for AML, certain inherited syndromes, and preexisting bone-marrow disorders. Some viruses are linked to rare leukemia types.
Most leukemia is not inherited directly. Families can share susceptibility, but relatives do not routinely need testing unless a genetics professional identifies a specific syndrome. Leukemia is not contagious.
THE BLACK HEALTH LENS
Combined U.S. leukemia incidence is lower among non-Hispanic Black people than among non-Hispanic White people, but an average across all leukemias hides important differences in subtype, age, diagnosis, treatment, and survival. Lower incidence must never be interpreted as protection for an individual with concerning symptoms or an abnormal blood count.
Structural factors can influence how quickly a patient reaches hematology care, receives molecular testing, enters a clinical trial, or accesses a transplant center. Insurance barriers, travel distance, time away from work, caregiver needs, and unequal referral patterns affect treatment choices that may look purely medical on paper. Clinicians should explain every reasonable option and discuss financial and logistical support early.
Stem-cell transplant illustrates why representation matters. Donors and patients are matched using inherited HLA markers, and a person is more likely to match someone with similar ancestry. NMDP reports that patients from ethnically diverse backgrounds have historically had a lower chance of finding a fully matched unrelated donor because of HLA diversity and underrepresentation in registries. This is not a reason to assume transplant is impossible. Modern approaches may use haploidentical relatives, cord blood, mismatched unrelated donors, and improved preventive treatments. Every eligible patient deserves timely referral and a full donor search.
Black patients also deserve adequate pain control and respectful evaluation of fatigue, bruising, and recurrent infection. Race should not substitute for genetic testing of the leukemia itself. Molecular findings in cancer cells—not racial categories—guide targeted therapy.
DIAGNOSIS
A complete blood count measures red cells, white cells, and platelets and reports white-cell subtypes. Leukemia may produce high, normal, or low white counts. A peripheral smear lets a laboratory specialist examine cell appearance. Abnormal results require interpretation; a single elevated white count during infection is not leukemia.
Bone marrow aspiration and biopsy commonly confirm acute leukemia and classify many chronic disorders. A clinician numbs the skin and bone, usually near the back of the hip, and removes liquid marrow and a small core. Pressure and brief sharp pain can occur despite local anesthetic; patients can ask about anxiety and pain-control options.
Flow cytometry identifies proteins on cells and helps define lineage. Cytogenetic tests look for chromosome changes; molecular tests detect gene variants or fusions. These results establish risk, identify targets, and provide markers for measurable residual disease. Imaging and lumbar puncture are used when clinically indicated, not for every case.
Staging differs from solid tumors. ALL and AML are described by subtype, genetics, response, and whether disease is new, in remission, refractory, or relapsed. CLL uses Rai or Binet staging; CML has chronic, accelerated, and blast phases.
TREATMENT
Treatment should be led by hematology-oncology specialists. Getting a second opinion at an experienced center can be valuable, especially for acute leukemia, transplant decisions, rare subtypes, or a clinical trial. Treatment may need to begin quickly, but essential diagnostic samples should be obtained first when medically safe.
Acute leukemia treatment
Therapy often has phases: induction aims for remission, consolidation reduces remaining disease, and maintenance is used in many ALL regimens but less often in AML. Medicines may include traditional chemotherapy, targeted agents, antibodies, antibody-drug conjugates, or other immunotherapies. Some ALL can be treated with CAR T-cell therapy. Stem-cell transplant may be recommended based on genetics, response, measurable residual disease, relapse risk, and health.
Acute promyelocytic leukemia is treated differently, often with all-trans retinoic acid and arsenic-based therapy. Because bleeding can begin before confirmation, suspected cases require immediate specialist action.
Chronic leukemia treatment
Many people with early, asymptomatic CLL are monitored without immediate therapy. This “watch and wait” approach avoids side effects because early treatment has not helped every low-risk patient. Treatment begins when evidence-based indications appear, such as progressive marrow failure, bulky or symptomatic nodes, rapid progression, or significant disease symptoms.
CML is generally treated with an oral BCR::ABL1 tyrosine-kinase inhibitor. Regular molecular blood tests track response. Adherence, interactions, side effects, pregnancy plans, and cardiovascular risk require discussion. A small, carefully selected group with deep, sustained response may attempt treatment-free remission under close specialist monitoring; stopping medicine independently is unsafe.
SUPPORTIVE CARE
Supportive care is active treatment. It may include red-cell or platelet transfusions, antibiotics, antivirals or antifungals, anti-nausea medicines, tumor-lysis prevention, growth factors in selected settings, pain control, nutrition, rehabilitation, and mental-health care. Blood products may require special processing.
Ask before receiving vaccines. Inactivated vaccines may be appropriate, while live vaccines can be unsafe during major immune suppression. Household members may also need guidance. Fertility preservation should be discussed before urgent treatment whenever time allows.
Clinical trials can offer promising therapy but do not guarantee benefit. Patients should understand the study phase, alternatives, costs, extra visits, and what happens if the treatment does not work.
PREVENTION AND SCREENING
There is no routine leukemia screening for asymptomatic people and no proven way to prevent most cases. Avoid smoking and unnecessary benzene exposure, follow workplace protections, and discuss long-term surveillance after prior cancer therapy. Do not obtain repeated blood counts without a clinical reason; screening can produce false alarms without preventing disease.
COMPLICATIONS AND OUTLOOK
Complications arise from leukemia and treatment: infection, anemia, bleeding, clotting, tumor lysis, organ infiltration, medication toxicity, infertility, and later cancers. Long-term survivors may need heart, endocrine, bone, cognitive, and psychosocial follow-up.
Outlook varies enormously by subtype. SEER estimates a 68.6% five-year relative survival for all U.S. leukemias combined for 2016–2022, but this number cannot predict an individual. Age, genetic findings, response, treatment access, and leukemia type matter. Some childhood ALL and chronic leukemias have high long-term control rates; some acute leukemias remain difficult. “Remission” means signs of disease are greatly reduced; it is not always identical to cure.
MYTHS AND FACTS
Myth: Leukemia always produces a very high white-cell count.
Fact: Counts may be high, normal, or low.
Myth: Every leukemia needs immediate chemotherapy.
Fact: Acute leukemias are urgent, while selected chronic leukemia is safely observed.
Myth: A stem-cell transplant requires a perfectly matched sibling.
Fact: Unrelated, haploidentical, cord-blood, and mismatched approaches may be options.
Myth: Leukemia is one disease with one survival rate.
Fact: Subtypes and molecular features have very different treatments and outcomes.
QUESTIONS TO ASK THE CARE TEAM
– What exact leukemia subtype and molecular findings do I have?
– How urgent is treatment, and is a second opinion safe?
– What is the goal: cure, long-term control, or symptom relief?
– How will response and measurable residual disease be monitored?
– Should transplant or a clinical trial be considered?
– What fever threshold requires an immediate call?
– How will fertility, finances, transportation, and caregiving be addressed?
FREQUENTLY ASKED QUESTIONS
Is leukemia curable?
Some leukemias can be cured; others can be controlled for years. The answer depends on subtype, genetics, age, response, and available treatment.
Can leukemia be found on a routine blood test?
Sometimes. An abnormal count can raise suspicion, but specialized testing is required.
Can leukemia spread from one person to another?
No. Leukemia is not contagious.
Does remission mean the cancer is gone forever?
Not necessarily. Remission means disease is no longer detectable by specified criteria or is greatly reduced. Monitoring continues for relapse.
MEDICAL DISCLAIMER
This information is educational and cannot diagnose leukemia or select treatment. An abnormal blood count requires professional interpretation. During treatment, fever, uncontrolled bleeding, breathing difficulty, confusion, or severe weakness requires immediate medical guidance or emergency care..
Black Health Thrive contributor
Medicine & Surgery
1. National Cancer Institute. Leukemia—Patient Version. https://www.cancer.gov/types/leukemia
2. National Cancer Institute. Adult Acute Myeloid Leukemia Treatment. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
3. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment. https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq
4. National Cancer Institute. Chronic Myelogenous Leukemia Treatment. https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq
5. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia. https://seer.cancer.gov/statfacts/html/leuks.html
6. NMDP. Why Ethnicity Matters for Bone Marrow Transplants. https://www.nmdp.org/en/get-involved/join-the-registry/ethnicity-and-diversity-matter
Medical review completed 2026-09-22.